Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

European biotech industry sees success and optimism rise over new Horizon

Authored by Karl Simpson The biotech business has been a tough business over recent years, not least in European where the business climate has been a little tricky to say the least. So the succession of positive news stories emanating … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Complix raises $15m for Alphabody pre-clinical work

Authored by James Sheppard The Belgian based biotech firm Complix announced that it had raised $15.5m in series B funding to develop its novel approach to protein therapeutics. Complix added a number of new investors in this round including company … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , | Leave a comment

Seattle Genetics strike another alliance deal with Bayer

Authored by Karl Simpson Another Day Completed, Another Deal Concluded for an Antibody Drug Conjugates. The antibody market is clearly nothing new but there is renewed focus in the potential of full humanised antibodies and Antibody Drug Conjugates (ADCs). Seattle … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment

Verastem secures orphan status from EMA for rare cancer mesothelioma

Authored by Karl Simpson US Biotech Verastem Inc. who develop drugs in the cancer therapy market have received orphan drug status, from the EMA, for its clinical candidate VS-6063. The drug is indicated for a rare disease called Mesothelioma, which … Continue reading

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , | Leave a comment

Polyphor begin Board succession with appointment of pharmaceutical Senior Executives

Authored by Karl Simpson Polyphor is a company nestled in the BioValley, Switzerland and is focused on the research and development of macrocyclic drugs. The company’s drug discovery technology platform has enabled them to build a pipeline of drug candidates … Continue reading

Posted in Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

Inflection Biosciences closes initial funding round and licenses new compounds

Authored by James Sheppard The Irish biotech Inflection Biosciences has closed its seed round of funding. The funding has primarily come from a private investor and Enterprise Ireland. The funds will primarily be used to advance the company’s development pipeline. … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , | Leave a comment

Biotech IPO fever spreads from West to East

Authored by Karl Simpson There has been much fanfare at the opening of the IPO window for biotechs in the US and already this year we have seen 17 new biotechs raise capital by taking their companies public, the most … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

Kurma Life Science Partners Launches new Biotech Fund for Rare Diseases

Authored by Karl Simpson The French venture capital company Kurma Life Science Partners (KLS Partners) announced the launch of a new fund specifically targeted at financing innovation in the field of rare disease research. The fund which has raised E44m … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Bluebird IPO shows gene therapy on upward trajectory

Authored by James Sheppard Gene therapy was again in the spotlight as the Boston based Bluebird bio completed its initial public offering (IPO). This further fuels what has been an impressive momentum swing for the area of gene therapy. Bluebird … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Johnson & Johnson grows prostate cancer franchise with Aragon purchase

Authored by James Sheppard The global pharmaceutical giant Johnson & Johnson (J&J) announced that it has completed the purchase of US biotech Aragon Pharmaceuticals, in a deal that could be worth up to $1bn. The deal is comprised of $650m … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap